| Drug General Information |
| Drug ID |
D00RSK
|
| Former ID |
DCL000830
|
| Drug Name |
GW-406381
|
| Synonyms |
GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene
|
| Drug Type |
Small molecular drug
|
| Indication |
Osteoarthritis; Neuropathic pain [ICD9: 338, 356.0, 356.8, 715,780; ICD10:G64, G90.0, M15-M19, M47, R52, G89]
|
Discontinued in Phase 3 |
[1]
|
|---|
| Therapeutic Class |
Analgesics
|
| Company |
GlaxoSmithKline
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H19N3O3S
|
| Canonical SMILES |
CCOC1=CC=C(C=C1)C2=NN3C(=C2C4=CC=C(C=C4)S(=O)(=O)C)C=CC<br />=N3
|
| InChI |
1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3
|
| InChIKey |
NXMZBNYLCVTRGB-UHFFFAOYSA-N
|
| CAS Number |
CAS 478702-57-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14927833, 24132908, 44930798, 79751754, 103452401, 104041733, 128768822, 135262831, 135263290, 137060736, 196381705, 198966530, 223793316, 226648697, 252160618
|
| Target and Pathway |
| Target(s) |
Prostaglandin G/H synthase 2 |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Aspirin-triggered lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
C20 prostanoid biosynthesis
|
|
Aspirin triggered resolvin E biosynthesis
|
|
KEGG Pathway
|
Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
NF-kappa B signaling pathway
|
|
VEGF signaling pathway
|
|
TNF signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Leishmaniasis
|
|
Pathways in cancer
|
|
Chemical carcinogenesis
|
|
MicroRNAs in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Endothelin signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Toll receptor signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
S1P1 pathway
|
|
C-MYB transcription factor network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
PathWhiz Pathway
|
Arachidonic Acid Metabolism
|
|
WikiPathways
|
Prostaglandin Synthesis and Regulation
|
|
Arachidonic acid metabolism
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. |
|---|
